Related Experiment Video

Updated: Apr 10, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.8K

Androgen pathway resistance in prostate cancer and therapeutic implications

Benjamin L Maughan1, Emmanuel S Antonarakis

  • 1Johns Hopkins Sidney Kimmel Comprehensive Cancer Center , 1650 Orleans St. CRB1 186, Baltimore, MD USA.

Expert Opinion on Pharmacotherapy
|June 13, 2015
PubMed
Abstract

Insights

Understanding resistance to advanced prostate cancer treatments is key. This review explores androgen receptor pathway resistance mechanisms and new therapeutic strategies for metastatic castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Metastatic prostate cancer is an incurable disease.
  • Hormonal therapies targeting the androgen receptor (AR) pathway are common treatments.
  • Patients invariably develop resistance, leading to castration-resistant prostate cancer.

Purpose of the Study:

  • To explore resistance mechanisms relevant to hormonal agents in metastatic castration-resistant prostate cancer.
  • To discuss novel therapeutic approaches informed by resistance insights.
  • To identify clinical trials related to androgen therapy resistance.

Main Methods:

  • Literature search for published clinical trials.
  • Review of resistance mechanisms, including AR-V7 expression.
  • Exploration of new treatment strategies for castration-resistant prostate cancer.

Main Results:

  • Androgen therapy resistance mechanisms are diverse, affecting the entire androgen signaling pathway.
  • Current optimal treatment for relapsed metastatic castration-resistant prostate cancer remains uncertain.
  • Available clinical data should guide treatment decisions.

Conclusions:

  • Resistance to androgen deprivation therapy is complex and multifactorial.
  • Novel therapies are emerging to overcome resistance.
  • Biomarker development is crucial for personalized treatment of metastatic castration-resistant prostate cancer.
Keywords:
AR-V7androgen receptorhormone resistancemetastatic castration-resistant prostate cancertreatment sequence

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K